Shares of GoodRx Holdings, Inc. (NASDAQ: GDRX) surged 5.98% in after-hours trading on Wednesday following the release of its first-quarter 2025 financial results. The leading platform for medication savings in the U.S. reported in-line revenue and beat expectations on adjusted EBITDA, while also raising its full-year adjusted EBITDA guidance.
For the first quarter, GoodRx reported revenue of $203.0 million, meeting analyst estimates. The company's adjusted EBITDA came in at $69.8 million, surpassing the expected $67 million. Notably, the adjusted EBITDA margin reached 34.4%, exceeding previous guidance and demonstrating improved profitability.
Investors were particularly encouraged by GoodRx's outlook. While maintaining its full-year 2025 revenue guidance range of $810 to $840 million, the company raised its adjusted EBITDA expectations. For the second quarter, management anticipates revenue to increase sequentially from Q1's $203 million, with an adjusted EBITDA margin similar to the first quarter's strong performance. This positive outlook, combined with the better-than-expected Q1 results, likely fueled the after-hours stock price jump as investors showed increased confidence in GoodRx's growth trajectory and profitability potential.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.